CRISPR/Cas9 system was used to inhibit TRPM7 and Orai1 in NSCLC NCI-H292 cells and cell invasion, which is a critical step in the metastatic process, was determined by the transwell assay. This evidence concerns the gene TRPM7 and non-small cell lung carcinoma.